Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023

VIENNA, Austria, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry. “It is an incredible honor to be recognized as one of the Fierce 15 biotech companies for 2023,” said Bernd Boidol, Ph.D., chief executive offi

見時知幾：2023 年Fierce15 藥企預示着哪些投資趨勢- LongPort

Chris Jenkins على LinkedIn: #genetherapy #community

Mitchell Pease on LinkedIn: #innovation #biotech #lifesciences

Mark Federici on LinkedIn: Crossbow Therapeutics Launches with $80

Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023

Fierce Biotech on LinkedIn: Takeda bets $4B upfront on Nimbus

Introducing Fierce Biotech's 2023 Fierce 15

Jacob Perrett on LinkedIn: #analyticaldevelopment #sec

Georg Winter (@georg_e_winter) / X